FilingPulse

TRAX insider transaction filings

First Tracks Biotherapeutics, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen TRAX transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-184Faga Daniel — President, CEO, DirectorGrant/award (A): 193,575 (derivative) @ $0EDGAR
2026-08-184Lizzul Paul F. — Chief Medical OfficerGrant/award (A): 60,492 (derivative) @ $0EDGAR
2026-08-184STONE BENJAMIN — Chief Business OfficerGrant/award (A): 60,492 (derivative) @ $0EDGAR
2026-08-054STONE BENJAMIN — Chief Business OfficerGrant/award (A): 60,492 (derivative) @ $0EDGAR
2026-08-054Faga Daniel — President, CEO, DirectorGrant/award (A): 193,576 (derivative) @ $0EDGAR
2026-08-054Lizzul Paul F. — Chief Medical OfficerGrant/award (A): 60,492 (derivative) @ $0EDGAR
2026-06-174Ware J. Anthony — DirectorOption exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-174Jain Rita — DirectorOption exercise (M): 7,330 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 · Option exercise (M): 1,300 (derivative) @ $0EDGAR
2026-06-174Marquet Magda — DirectorOption exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-174Schmid John P. — DirectorOption exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-174Orwin John A — DirectorOption exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-174FENTON DENNIS M — DirectorOption exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-124/AWare J. Anthony — DirectorGrant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-124/AJain Rita — DirectorGrant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-124/AMarquet Magda — DirectorGrant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-124/ASchmid John P. — DirectorGrant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-124/AOrwin John A — DirectorGrant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-124/AFENTON DENNIS M — DirectorGrant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-05-144STONE BENJAMIN — Chief Business OfficerGrant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 72,300 (derivative) @ $0EDGAR
2026-05-144Tamboli Ajim — Chief Financial OfficerGrant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 13,600 (derivative) @ $0EDGAR
2026-05-144Ware J. Anthony — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-05-144Lizzul Paul F. — Chief Medical OfficerGrant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 72,300 (derivative) @ $0EDGAR
2026-05-144Jain Rita — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-05-144Faga Daniel — President, CEO, DirectorGrant/award (A): 100,200 (derivative) @ $0 · Grant/award (A): 271,100 (derivative) @ $0EDGAR
2026-05-144Marquet Magda — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-05-144Schmid John P. — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-05-144Orwin John A — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-05-144FENTON DENNIS M — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-04-234Tamboli Ajim — Chief Financial OfficerGrant/award (A): 45,700 (derivative) @ $0 · Grant/award (A): 41,233 (derivative) @ $0 · Grant/award (A): 41,233 (derivative) @ $0 · Grant/award (A): 41,234 (derivative) @ $0EDGAR
2026-04-224Ware J. Anthony — DirectorGrant/award (A): 28,571 (derivative) @ $0 · Grant/award (A): 10,694 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · +7 moreEDGAR
2026-04-224Lizzul Paul F. — Chief Medical OfficerGrant/award (A): 83,500 (derivative) @ $0 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 67,070 (derivative) @ $0 · Grant/award (A): 115,540 (derivative) @ $0 · Grant/award (A): 97,200 (derivative) @ $0 · +5 moreEDGAR
2026-04-224Jain Rita — DirectorGrant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 8,015 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 1,300 (derivative) @ $0 · +2 moreEDGAR
2026-04-224Faga Daniel — President, CEO, DirectorGrant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 2,321 (derivative) @ $0 · Grant/award (A): 9,200 (derivative) @ $0 · Grant/award (A): 194,900 (derivative) @ $0 · Grant/award (A): 379,620 (derivative) @ $0 · Grant/award (A): 305,500 (derivative) @ $0 · +5 moreEDGAR
2026-04-224Marquet Magda — DirectorGrant/award (A): 784 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 9,200 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · +3 moreEDGAR
2026-04-224EcoR1 Capital, LLC — 10% ownerSale (S): 4,705,575 @ $13.81EDGAR
2026-04-224Schmid John P. — DirectorGrant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 9,200 (derivative) @ $0 · +6 moreEDGAR
2026-04-224Orwin John A — DirectorGrant/award (A): 3,311 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 8,250 (derivative) @ $0 · Grant/award (A): 1,300 (derivative) @ $0 · +2 moreEDGAR
2026-04-224ANAPTYSBIO, INC — 10% ownerOther (J): 100EDGAR
2026-04-224FENTON DENNIS M — DirectorGrant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 5,507 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 9,200 (derivative) @ $0 · +6 moreEDGAR

Recent 8-K events — First Tracks Biotherapeutics, Inc.

FiledFormItems reportedSource
2026-08-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-06-228-K1.01 — Entry into a Material Definitive AgreementEDGAR
2026-05-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-04-208-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-04-038-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TRAX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →